CG:603520 Zhejiang Starry Pharmaceutical Co., Ltd

Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of active ingredient and intermediate X-CT non-ionic contrast agents, and fluoroquinolones in China and internationally. The company's contrast medium products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, gadobenate dimeglumine, iodixanol, gadopentetate dimeglumine, and gadoterate meglumine; and fluoroquinolones products comprise levofloxacin hemihydrate, levofloxacin HCL, levofloxacin acid ester, levofloxacin acid, pazufloxacin, and pazufloxacin mesylate. Zhejiang Starry Pharmaceutical Co., Ltd. was founded in 1997 and is based in Xianju, China.

51.76 CNY
As of 01/25/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Unknown
Industry:  Drug Manufacturers-Specialty &
Index country:  China
Country of incorporation:  China
IPO date:  03/09/2016
Stock exchange:    Shanghai Stock Exchange
Exchange country:   China
Market cap:   13,022,653,440 CNY
Current dividend yield:   0.92%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy